The therapeutic potential of royal jelly in benign prostatic hyperplasia. Comparison with contemporary literature

References

• Roehrborn CG, McConnell J, Bonilla J, et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol 2000;163:13–20
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Boyle P, Bergner D, et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. Urology 1999;54:662–9
   PubMed Web of Science ®Google Scholar
• Lunenfeld B, Maskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male 2015;18:5–15
   PubMed Web of Science ®Google Scholar
• Gratzke C, Bachmann A, Descazeaud A, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2015;67:1099–109
   PubMed Web of Science ®Google Scholar
• Barry MJ, Fowler FJ Jr, O’Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992;148:1549–57
   PubMed Web of Science ®Google Scholar
• Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 2005;31:664–73
   PubMed Web of Science ®Google Scholar
• Seftel AD. Finasteride, not tamsulosin increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia. J Urol 2016;195:139. doi:10.1016/j.juro.2015.10.071
   PubMed Web of Science ®Google Scholar
• van Dijk MM, de la Rosette JJ, Michel MC. Effects of alpha(1)-adrenoceptor antagonists on male sexual function. Drugs 2006;66:287–301
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Ray P. Efficacy and tolerability of the dual 5alpha-reductase inhibitor, dutasteride, in the treatment of benign prostatic hyperplasia in African-American men. Prostate Cancer Prostatic Dis 2006;9:432–8
   PubMed Web of Science ®Google Scholar
• Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract 2008;62:1547–59
   PubMed Web of Science ®Google Scholar
• Cheetham PJ. Role of complimentary therapy for male LUTS. Curr Urol Rep 2013;14:606–13
   PubMed Web of Science ®Google Scholar
• Tacklind J, Macdonald R, Rutks I, et al. Serenoa repens for benign prostatic hyperplasia. Cohrane Database Syst Rev 2012;12:CD001423
   PubMedGoogle Scholar
• MacDonald R, Tacklind JW, Rutks I, et al. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review. BJU Int 2012;109:1756–61
   PubMed Web of Science ®Google Scholar
• Valiollahpoor Amiri M, Deldar H, Ansari Pirsaraei Z. Impact of supplementary royal jelly on in vitro maturation of sheep oocytes: genes involved in apoptosis and embryonic development. Syst Biol Reprod Med 2016;62:31–8
   PubMed Web of Science ®Google Scholar
• Alan Z, Askoy L. Anti-inflamatory effects of royal jelly on ethylene glycol induced renal inflammation in rats. Int Braz J Urol 2015;41:1008–13
   PubMed Web of Science ®Google Scholar
• Erem C, Deger O, Ovali E, et al. The effects of royal jelly on autoimmunity in Graves’ disease. Endocrine 2006;30:175–83
   PubMed Web of Science ®Google Scholar
• Izuta H, Chikaraishi Y, Shimazawa M, et al. 10-Hydroxy-2-decenoic acid, a major fatty acid from royal jelly, inhibits VEGF-induced angiogenesis in human umbilical vein endothelial cells. Evid Based Complement Alternat Med 2009;6:489–94
   PubMed Web of Science ®Google Scholar
• Krylov V, Agafonov A, Krivtsov N, et al. Theory and agents of apitherapy. Moscow: Comme it faut Publishers; 2007 (in Russian)
   Google Scholar
• Agency for Health Care Policy and Research. Clinical practice guideline: urinary incontinence in adults. AHPCR Pub. No. 96-0682. Rockville (MD): Dept of Health and Human Services (US), Agency for Health Care Policy and Research; 1996
   Google Scholar
• Cheah PY, Liong M, Yuen KH, et al. Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. J Urol 2003;169:592–6
   PubMed Web of Science ®Google Scholar
• Morgia G, Mucciardi G, Gali A, et al. Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter-controlled study. Urol Int 2010;84:400–6
   PubMed Web of Science ®Google Scholar
• Wehrberger C, Dreikorn K, Schmitz-Drager BJ, et al. Phytotherapy of benign prostate syndrome and prostate cancer: better than placebo. Urologe A 2012;51:1674–82
   PubMedGoogle Scholar
• Sinescu l, Geavlete P, Multescu R, et al. Long-term efficacy of Serenoa repens treatment in patients with mild and moderate symptomatic benign prostatic hyperplasia. Urol Int 2011;86:284–9
   PubMed Web of Science ®Google Scholar
• Tacklind J, MacDonald R, Rutks I, et al. Serenoa repens for benign prostatic hyperplasia. Cohrane Database Syst Rev 2009;15:CD001423
   Google Scholar
• Djavan B, Fong YK, Harik M, et al. Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. Urology 2004;64:1144–8
   PubMed Web of Science ®Google Scholar
• Michel MC, Mehlburger L, Bressel HU, et al. Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms. Prostate Cancer Prostatic Dis 1998;1:332–5
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Siami P, Barkin J, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008;179:616–21
   PubMed Web of Science ®Google Scholar
• Ryu YW, Lim SW, Kim JH, et al. Comparison of tamsulosin plus Serenoa repens with tamsulosin in the treatment of benign prostatic hyperplasia in Korean men: 1-year randomized open label study. Urol Int 2015;94:187–93
   PubMed Web of Science ®Google Scholar
• Argirovic A, Argirovic D. Does the addition of Serenoa repens to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia? Vojnosanit Pregl 2013;70:1091–6
   PubMed Web of Science ®Google Scholar
• Morgia G, Russo GI, Voce S, et al. Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial). Prostate 2014;74:1471–80
   PubMed Web of Science ®Google Scholar
• Bohnen AM, Groeneveld FP, Bosch JL. Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study. Eur Urol 2007;51:1645–52
   PubMed Web of Science ®Google Scholar
• Wilt T, Ishani A, Stark G, et al. Serenoa repens for benign prostatic hyperplasia. Cohrane Database Syst Rev 2000;2:CD001423
   Google Scholar
• Andriole GL, McCullum-Hill C, Sandhu GS, et al. The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial. J Urol 2013;189:486–92
   PubMed Web of Science ®Google Scholar
• Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clin Ther 2007;29:17–25
   PubMed Web of Science ®Google Scholar
• Silici S, Ekmekcioglu O, Eraslan G, et al. Antioxidative effect of royal jelly in cisplatin-induced testes damage. Urology 2009;74:545–51
   PubMed Web of Science ®Google Scholar
• Viuda-Martos M, Ruiz-Navajas Y, Fernandez-Lopez J, Perez-Alvarez JA. Functional properties of honey, propolis and royal jelly. J Food Sci 2008;73:117–24
   PubMed Web of Science ®Google Scholar
• Kohno K, Okamoto I, Sano O, et al. Royal jelly inhibits the production of proinflammatory cytokines by activated macrophages. Biosci Biotechnol Biochem 2004;68:138–45
   PubMed Web of Science ®Google Scholar
• Guo H, Saiga A, Sato M, et al. Royal jelly supplementation improves lipoprotein metabolism in humans. J Nutr Sci Vitaminol (Tokyo) 2007;53:345–8
   PubMed Web of Science ®Google Scholar